UiO - Det odontologiske fakultet

Large grant to research on antibiotic resistance in prematurely born infants

Del

Professor Fernanda Petersen at the Department of Oral Biology (UiO) has been awarded, together with her partners, a large grant from the Olav Thon Foundation. The grant was given the research project: «Born in the twilight of antibiotics: fighting antimicrobial resistance in preterm infants».

Fernanda Petersen (right) and Thomas Kuntziger, whom collaborates on Petersen's Research Projects. Photo: Faculty of Dentistry, University of Oslo/Margit Selsjord.
Fernanda Petersen (right) and Thomas Kuntziger, whom collaborates on Petersen's Research Projects. Photo: Faculty of Dentistry, University of Oslo/Margit Selsjord.

The grant is parts of the funds for Nordic medical research collaborations.

– This is a very important grant and it enables a significant focus on the health of prematurely born infants. Hopefully, it will lead to measures that may contribute to reduce the challenges with antibiotic resistant organisms, that this vulnerable group is experiencing, says Petersen.

Petersen’s partners on the project is Danish Professor Gorm Greisen from the University of Copenhagen and Swedish Professor Anders Håkansson from the University of Lund. Her Norwegian partners are Dr. Kirsti Haaland, Professor Dag Berild, and Professor Ola Didrik Saugstad from Oslo University Hospital, Specialist Director at the Norwegian Institute of Public Health, Ulf R. Dahle, and colleague Thomas M. Kuntziger, Associate Professor at the Department of Oral Biology, at the Faculty of Dentistry.

Latest out of a number of grants

This Olav Thon Foundation grant is the latest in a line of significant grants for Petersen and her colleagues, and their research on antibiotic resistance. In October they received funds from the Norwegian Research Council to a substantial research collaboration with Indian and Norwegian health authorities. The project seeks to find better strategies to protect prematurely born infants against infections resistant to antiobiotics.

In addition, Petersen received a grant in November, to another international research and educational collaboration: «Enhancing world-class research and education in biofilm and antibiotic resistance by strengthening cooperation between Norway-Brazil-USA».

– This grant from the Olav Thon Foundation helps strengthen the network and the projects that have already been started. This grants the projects a Nordic angle and altogether, they will prove a significant contribution to a large and growing global health problem, says Petersen.

She adds that a joint goal for the projects is to inform and educate about antibiotic resistance, and to identify methods and routines that reduce the risk of spreading and developing the resistance further.

– It’s a long way to go. We are going to create web lectures, use advanced analyses, so-called metagenome-analyses, and animal trials. I am looking forward to get started and I am excited about both recruiting, analyzing and interpreting data together with the solid network we have established.

Nøkkelord

Kontakter

Bilder

Fernanda Petersen (right) and Thomas Kuntziger, whom collaborates on Petersen's Research Projects. Photo: Faculty of Dentistry, University of Oslo/Margit Selsjord.
Fernanda Petersen (right) and Thomas Kuntziger, whom collaborates on Petersen's Research Projects. Photo: Faculty of Dentistry, University of Oslo/Margit Selsjord.
Last ned bilde

Lenker

Om UiO - Det odontologiske fakultet

UiO - Det odontologiske fakultet
UiO - Det odontologiske fakultet
Geitmyrsveien 69
0455 Oslo

22852000http://www.odont.uio.no/

Følg saker fra UiO - Det odontologiske fakultet

Registrer deg med din epostadresse under for å få de nyeste sakene fra UiO - Det odontologiske fakultet på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra UiO - Det odontologiske fakultet

Skreddersydd kreftbehandling21.6.2017 11:54Pressemelding

I Norge er det stadig flere som rammes av munn og halskreft. Forekomsten har økt de siste årene mens dødeligheten har forblitt uendret. Cisplatin er en av de vanligste cellegiftene å gi til denne pasientgruppen. I begynnelsen av behandlingen virker cellegiften bra, men etter hvert vil de fleste pasientene oppleve at svulsten utvikler resistens mot denne cellegiften og prognosene for overlevelse blir da svært dårlig. Forskerne Jian Gao og professor Trond Sundby Halstensen har prøvd å finne mekanismen bak denne resistensen.

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom